• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原位心脏移植术后血管麻痹:发生率、预测因素和临床结局。

Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes.

机构信息

Department of Cardiology, Alfred Health, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Department of Cardiology, Alfred Health, Melbourne, Australia.

出版信息

J Card Fail. 2022 Apr;28(4):617-626. doi: 10.1016/j.cardfail.2021.11.020. Epub 2021 Dec 30.

DOI:10.1016/j.cardfail.2021.11.020
PMID:34974975
Abstract

BACKGROUND

Patients undergoing heart transplant are at high risk for postoperative vasoplegia. Despite its frequency and association with poor clinical outcomes, there remains no consensus definition for vasoplegia, and the predisposing risk factors for vasoplegia remain unclear. Accordingly, the aim of this study was to evaluate the prevalence, predictors, and clinical outcomes associated with vasoplegia in a contemporary cohort of patients undergoing heart transplantation.

METHODS

This was a retrospective cohort study of patients undergoing heart transplantation from January 2015 to December 2019. A binary definition of vasoplegia of a cardiac index of 2.5 L/min/m or greater and requirement for norepinephrine (≥5 µg/min), epinephrine (≥4 µg/min), or vasopressin (≥1 unit/h) to maintain a mean arterial blood pressure of 65 mm Hg, for 6 consecutive hours during the first 48 hours postoperatively, was used in determining prevalence. Given the relatively low threshold for the binary definition of vasoplegia, patients were divided into tertiles based on their cumulative vasopressor requirement in the 48 hours following transplant. Outcomes included all-cause mortality, intubation time, intensive care unit length of stay, and length of total hospitalization.

RESULTS

After exclusion of patients with primary cardiogenic shock, major bleeding, or overt sepsis, data were collected on 95 eligible patients. By binary definition, vasoplegia incidence was 66.3%. We separately stratified by actual vasopressor requirement tertile (high, intermediate, low). Stratified by tertile, patients with vasoplegia were older (52.7 ± 10.2 vs 46.8 ± 12.7 vs 44.4 ± 11.3 years, P = .02), with higher rates of chronic kidney disease (18.8% vs 32.3% vs 3.1%, P = .01) and were more likely to have been transplanted from left ventricular assist device support (n = 42) (62.5% vs 32.3% vs 37.5%, P = .03). Cardiopulmonary bypass time was prolonged in those that developed vasoplegia (155 min [interquartile range 135-193] vs 131 min [interquartile range 117-152] vs 116 min [interquartile range 102-155], P = .003). Intubation time and length of intensive care unit and hospital stay were significantly increased in those that developed vasoplegia; however, this difference did not translate to a significant increase in all-cause mortality at 30 days or 1 year.

CONCLUSIONS

Vasoplegia occurs at a high rate after heart transplantation. Older age, chronic kidney disease, mechanical circulatory support, and prolonged bypass time are all associated with vasoplegia; however, this study did not demonstrate an associated increase in all-cause mortality LAY SUMMARY: Patients undergoing heart transplantation are at high risk of vasoplegia, a condition defined by low blood pressure despite normal heart function. We found that vasoplegia was common after heart transplant, occurring in 60%-70% of patients after heart transplant after excluding those with other causes for low blood pressure. Factors implicated included age, poor kidney function, prolonged cardiopulmonary bypass time and preoperative left ventricular assist device support. We found no increased risk of death in patients with vasoplegia despite longer lengths of stay in intensive care and in hospital.

摘要

背景

接受心脏移植的患者术后发生血管麻痹的风险很高。尽管血管麻痹的发生频率很高,且与不良临床结局相关,但目前仍没有血管麻痹的共识定义,其易患风险因素也不明确。因此,本研究旨在评估在接受心脏移植的当代患者队列中血管麻痹的发生率、预测因素和临床结局。

方法

这是一项回顾性队列研究,纳入了 2015 年 1 月至 2019 年 12 月期间接受心脏移植的患者。采用心脏指数为 2.5 L/min/m 或更高,且需要去甲肾上腺素(≥5 µg/min)、肾上腺素(≥4 µg/min)或血管加压素(≥1 单位/h)来维持平均动脉血压在 65mmHg 以上,持续 6 小时的二元定义来确定血管麻痹的发生率。由于血管麻痹的二元定义阈值相对较低,因此根据术后 48 小时内的累积血管加压剂需求将患者分为三分位数。结局包括全因死亡率、插管时间、重症监护病房住院时间和总住院时间。

结果

排除了原发性心源性休克、大出血或明显败血症的患者后,共纳入了 95 名符合条件的患者。根据实际血管加压剂需求三分位数(高、中、低)进行分层。分层后,血管麻痹的发生率为 66.3%。我们分别按三分位数进行了分层(高、中、低)。按三分位数分层,血管麻痹患者年龄更大(52.7 ± 10.2 岁比 46.8 ± 12.7 岁比 44.4 ± 11.3 岁,P =.02),慢性肾脏病发生率更高(18.8%比 32.3%比 3.1%,P =.01),更可能接受左心室辅助装置支持(n=42)(62.5%比 32.3%比 37.5%,P =.03)。发生血管麻痹的患者体外循环时间延长(155 分钟[四分位距 135-193]比 131 分钟[四分位距 117-152]比 116 分钟[四分位距 102-155],P =.003)。发生血管麻痹的患者插管时间和重症监护病房及住院时间明显延长;然而,这一差异并未导致 30 天或 1 年时全因死亡率的显著增加。

结论

心脏移植后血管麻痹的发生率很高。年龄较大、慢性肾脏病、机械循环支持和体外循环时间延长均与血管麻痹相关;然而,本研究并未显示血管麻痹与全因死亡率增加相关,尽管血管麻痹患者的重症监护病房和住院时间较长。

重点词汇:

  • vasoplegia:血管麻痹

  • cardiogenic shock:心源性休克

  • left ventricular assist device:左心室辅助装置

相似文献

1
Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes.原位心脏移植术后血管麻痹:发生率、预测因素和临床结局。
J Card Fail. 2022 Apr;28(4):617-626. doi: 10.1016/j.cardfail.2021.11.020. Epub 2021 Dec 30.
2
Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices.连续性血流左心室辅助装置桥接心脏移植患者血管扩张的预测因子和临床结局。
J Am Heart Assoc. 2019 Nov 19;8(22):e013108. doi: 10.1161/JAHA.119.013108. Epub 2019 Nov 8.
3
Vasoplegia after heart transplantation: outcomes at 1 year.心脏移植术后血管麻痹:1年时的结局
Interact Cardiovasc Thorac Surg. 2017 Aug 1;25(2):212-217. doi: 10.1093/icvts/ivx081.
4
Vasoplegia after pediatric cardiac transplantation in patients supported with a continuous flow ventricular assist device.儿童心脏移植术后应用连续血流心室辅助装置患者的血管扩张。
J Thorac Cardiovasc Surg. 2019 Jun;157(6):2433-2440. doi: 10.1016/j.jtcvs.2019.01.100. Epub 2019 Feb 6.
5
Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors.连续流左心室辅助装置植入术后血管麻痹:发生率、结局及预测因素
BMC Anesthesiol. 2018 Dec 8;18(1):185. doi: 10.1186/s12871-018-0645-y.
6
Determinants and Outcomes of Vasoplegia Following Left Ventricular Assist Device Implantation.左心室辅助装置植入术后血管扩张的决定因素和结果。
J Am Heart Assoc. 2018 May 17;7(11):e008377. doi: 10.1161/JAHA.117.008377.
7
Characterizing Predictors and Severity of Vasoplegia Syndrome After Heart Transplantation.描述心脏移植后血管扩张综合征的预测因子和严重程度。
Ann Thorac Surg. 2018 Mar;105(3):770-777. doi: 10.1016/j.athoracsur.2017.09.039. Epub 2017 Dec 28.
8
Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era.在当代,原位心脏移植受者并发血管麻痹的术前危险因素和临床结局。
J Heart Lung Transplant. 2012 Mar;31(3):282-7. doi: 10.1016/j.healun.2011.10.010. Epub 2011 Nov 23.
9
Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation.心脏移植术中体外循环后血管麻痹的发生率及影响
ASAIO J. 2018 Jan/Feb;64(1):43-51. doi: 10.1097/MAT.0000000000000623.
10
Predictors and Impact of Prolonged Vasoplegia After Continuous-Flow Left Ventricular Assist Device Implantation.连续流左心室辅助装置植入术后持续性血管麻痹的预测因素及影响
JACC Adv. 2024 Mar 26;3(5):100916. doi: 10.1016/j.jacadv.2024.100916. eCollection 2024 May.

引用本文的文献

1
Decreased vasoregulatory dysfunction associated with intra-operative hemoadsorption treatment is related to mitigated post-transplant procalcitonin rather than cytokine or complement response.与术中血液吸附治疗相关的血管调节功能障碍减轻与移植后降钙素原减轻有关,而非细胞因子或补体反应。
Front Med (Lausanne). 2025 Aug 13;12:1541519. doi: 10.3389/fmed.2025.1541519. eCollection 2025.
2
Glibenclamide Serves as a Potent Vasopressor to Treat Vasoplegia After Cardiopulmonary Bypass and Reperfusion in a Porcine Model.格列本脲作为一种强效血管升压药,用于治疗猪体外循环和再灌注后血管麻痹。
Int J Mol Sci. 2025 Apr 24;26(9):4040. doi: 10.3390/ijms26094040.
3
Intraoperative Hemoadsorption in Heart Transplant Surgery: A 5-Year Experience.
心脏移植手术中的术中血液吸附:5年经验
J Cardiovasc Dev Dis. 2025 Mar 28;12(4):119. doi: 10.3390/jcdd12040119.
4
Acute Kidney Injury after Heart Transplantation: Risk Stratification is Good; Risk Modification is Better-But can we do it?心脏移植术后急性肾损伤:风险分层有益;风险修正更佳——但我们能做到吗?
Transplant Direct. 2024 May 16;10(6):e1635. doi: 10.1097/TXD.0000000000001635. eCollection 2024 Jun.
5
Recipient Pericardial Apolipoprotein Levels Might Be an Indicator of Worse Outcomes after Orthotopic Heart Transplantation.受体心包脂类载脂蛋白水平可能是原位心脏移植后预后不良的一个指标。
Int J Mol Sci. 2024 Feb 1;25(3):1752. doi: 10.3390/ijms25031752.
6
Effects of ketone body 3-hydroxybutyrate on cardiac and mitochondrial function during donation after circulatory death heart transplantation.酮体 3-羟丁酸对心跳骤停后循环死亡供心移植中心脏和线粒体功能的影响。
Sci Rep. 2024 Jan 8;14(1):757. doi: 10.1038/s41598-024-51387-y.
7
Use of intraoperative haemoadsorption in patients undergoing heart transplantation: a proof-of-concept randomized trial.术中血液吸附在心脏移植患者中的应用:一项概念验证随机试验。
ESC Heart Fail. 2024 Apr;11(2):772-782. doi: 10.1002/ehf2.14632. Epub 2023 Dec 19.
8
Donor Pericardial Interleukin and Apolipoprotein Levels May Predict the Outcome after Human Orthotopic Heart Transplantation.供体心包白细胞介素和载脂蛋白水平可能预测人体原位心脏移植后的结局。
Int J Mol Sci. 2023 Apr 5;24(7):6780. doi: 10.3390/ijms24076780.